Anders Gabrielsen
Overview
Explore the profile of Anders Gabrielsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papworth M, Kulkarni S, Antonsson M, Sermadiras I, Hovdal D, Connolly K, et al.
Cardiovasc Res
. 2025 Mar;
PMID: 40037346
Aim: Relaxin-2, a well-known human hormone primarily associated with pregnancy, has shown promising cardiovascular benefits in both preclinical models and clinical trials. However, its therapeutic potential has been limited due...
2.
Connolly K, George R, Omar S, Matsson E, Astrand M, Althage M, et al.
J Am Heart Assoc
. 2024 Jul;
13(15):e034067.
PMID: 39056338
Background: Heart failure mortality remains high despite recent progress in pharmacological treatment. AZD3427 is a selective long-acting analog of relaxin, a vasodilatory hormone with antifibrotic effects. We assessed the safety,...
3.
Kardassis D, Egnell A, Astrand M, Daniels S, Whatling C, Fjellstrom O, et al.
J Am Heart Assoc
. 2024 May;
13(11):e033985.
PMID: 38804212
Background: ADP and ATP are importantly involved in vascular and thrombotic homeostasis, via multiple receptor pathways. Blockade of ADP P2Y receptors inhibits platelet aggregation and represents an effective cardiovascular disease...
4.
Lam C, Kober L, Kuwahara K, Lund L, Mark P, Mellbin L, et al.
Eur J Heart Fail
. 2024 May;
26(8):1727-1735.
PMID: 38783712
Aims: Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor...
5.
Voits T, DeLuca V, Hao J, Elin K, Abutalebi J, Dunabeitia J, et al.
Neurobiol Aging
. 2024 May;
140:70-80.
PMID: 38735176
Multilingualism has been demonstrated to lead to a more favorable trajectory of neurocognitive aging, yet our understanding of its effect on neurocognition across the lifespan remains limited. We collected resting...
6.
Vilahur G, Radike M, Sutelman P, Ben-Aicha S, Gutierrez M, Casani L, et al.
Eur Heart J
. 2024 Mar;
45(17):1553-1567.
PMID: 38486376
Background And Aims: The ecto-nucleoside triphosphate diphosphohydrolases of the CD39 family degrade ATP and ADP into AMP, which is converted into adenosine by the extracellular CD73/ecto-5-nucleotidase. This pathway has been...
7.
Lund L, Lam C, Pizzato P, Gabrielsen A, Michaelsson E, Nelander K, et al.
Eur J Heart Fail
. 2023 Jul;
25(9):1696-1707.
PMID: 37470101
Aims: Mitiperstat (formerly AZD4831) is a novel selective myeloperoxidase inhibitor. Currently, no effective therapies target comorbidity-induced systemic inflammation, which may be a key mechanism underlying heart failure with preserved or...
8.
Michaelsson E, Lund L, Hage C, Shah S, Voors A, Saraste A, et al.
JACC Heart Fail
. 2023 May;
11(7):775-787.
PMID: 37140510
Background: Systemic microvascular dysfunction and inflammation are postulated to play a pathophysiologic role in heart failure with preserved ejection fraction (HFpEF). Objectives: This study aimed to identify biomarker profiles associated...
9.
Lam C, Lund L, Shah S, Voors A, Erlinge D, Saraste A, et al.
J Card Fail
. 2023 Apr;
30(1):104-110.
PMID: 37072105
Background: Inflammation is a key driver of heart failure with preserved left ventricular ejection fraction. AZD4831 inhibits extracellular myeloperoxidase, decreases inflammation, and improves microvascular function in preclinical disease models. Methods...
10.
Squire I, Gabrielsen A, Greasley P, Wernevik L, Hartleib-Geschwindner J, Holden J, et al.
Clin Transl Sci
. 2022 Aug;
15(10):2493-2504.
PMID: 35971596
This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK ) in patients with heart...